Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058658 | 0.86 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL12978933 | 0.86 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL16033288 | 0.83 | ALDH1A1 (0.54) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL27700248 | 0.83 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL124590 | 0.82 | ALDH1A1 (0.63) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL3645769 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL18314720 | 0.82 | ALDH1A1 (0.56) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL113462 | 0.81 | NPC1 (0.53) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| Methane SCHEMBL25287143 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A | |
| SCHEMBL4043187 | 0.81 | ALDH1A1 (0.57) | ALDH1A1CYP2D6L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611461-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | CITY OF HOPE (US) | 2026-04-28 | — | — | US | disclosed |
| US-12589162-B2 | Trans-cyclooctene prodrug of monomethyl auristatin E | TAMBO, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORP (US) | 2026-01-29 | — | — | US | disclosed |
| US-12527874-B2 | Bioorthogonal compositions | TAMBO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260007759-A1 | TRANS-CYCLOOCTENE PRODRUG OF MONOMETHYL AURISTATIN E | TAMBO, INC. | 2026-01-08 | — | — | US | disclosed |
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368608-A1 | SELECTIVE HDAC6 INHIBITOR | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2025-12-04 | — | — | US | disclosed |
| WO-2003004479-A1 | 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-01-16 | — | — | WO | disclosed |
| US-20030008896-A1 | Isoquinolinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2003-01-09 | — | — | US | disclosed |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-12-05 | — | — | US | disclosed |
| WO-2002090334-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002036576-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002030879-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030932-A2 | N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002026696-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002026703-A1 | CARBAMIC ACID COMPOUNDS COMPRISING AN ETHER LINKAGE AS HDAC INHIBITORS | PROLIFIX LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002008193-A2 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | SLC6A3, SLC6A2, HTR2C | ALDH1A1 1951/4885CYP2D6 90/4885L3MBTL1 3879/4885 |
| US-20250368608-A1 | SELECTIVE HDAC6 INHIBITOR | HDAC6, HDAC3, HDAC1 | ALDH1A1 3394/4885CYP2D6 1297/4885L3MBTL1 3884/4885 |
| US-20250378926-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | ALDH1A1 2917/4885CYP2D6 4789/4885L3MBTL1 213/4885 |
| US-20020183325-A1 | Therapy of disease of the human or animal body mediated by poly ADP-ribosyltransferase (PARP) by administering phthalazinone derivatives | PARP1, PARP11, PARP3 | ALDH1A1 208/4885CYP2D6 1311/4885L3MBTL1 37/4885 |
| US-12589162-B2 | Trans-cyclooctene prodrug of monomethyl auristatin E | AURKC, AURKA, QPCT | ALDH1A1 2176/4885CYP2D6 2431/4885L3MBTL1 1775/4885 |
| US-20030008896-A1 | Isoquinolinone derivatives | PARP1, PARP2, PARP3 | ALDH1A1 534/4885CYP2D6 1330/4885L3MBTL1 1084/4885 |
| US-12611462-B2 | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof | STAT3, NSUN2, STAT1 | ALDH1A1 4751/4885CYP2D6 4594/4885L3MBTL1 1025/4885 |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, VIP, PREP | ALDH1A1 3849/4885CYP2D6 2205/4885L3MBTL1 269/4885 |
| US-12611461-B2 | Bioorthogonal compositions | ACVRL1, FCGR2A, CHIT1 | ALDH1A1 936/4885CYP2D6 2939/4885L3MBTL1 629/4885 |
| US-20260007759-A1 | TRANS-CYCLOOCTENE PRODRUG OF MONOMETHYL AURISTATIN E | CCL5, CXCL10, SLC7A11 | ALDH1A1 2829/4885CYP2D6 3340/4885L3MBTL1 2277/4885 |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | HTR2C, SLC6A2, DRD2 | ALDH1A1 1469/4885CYP2D6 92/4885L3MBTL1 3800/4885 |
| US-12527874-B2 | Bioorthogonal compositions | CD44, FLNA, H1-5 | ALDH1A1 663/4885CYP2D6 1689/4885L3MBTL1 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.